Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was ranked in Deloitte’s 2019 and 2020 Technology Fast 500™, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage pharmaceutical products and product candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital and Nationwide Children’s Hospital.
View Top Employees from Fortress BiotechWebsite | http://www.fortressbiotech.com |
Ticker | FBIO |
Revenue | $36 million |
Funding | $75 million |
Employees | 40 (40 on RocketReach) |
Founded | 2006 |
Address | 1111 Kane Concourse Suite 301, Bay Harbor Islands, Florida, US |
Phone | (781) 652-4500 |
Technologies |
JavaScript,
HTML,
PHP
+16 more
(view full list)
|
Industry | Pharmaceuticals, Biotechnology Research, Healthcare |
Web Rank | 3 Million |
Keywords | Fortress Biotech, Autoimmune Disease Graph 2002 Bach, The Effect Of Infections On Susceptibility To Autoimmune And Allergic Diseases, New York Therapeutic Companies, Bach, J.F. (2002) The Effect Of Infections On Susceptibility To Autoimmune And Allergic Diseases. N. Engl. J. Med. 347, 911–920 |
Competitors | Cancer Prevention Pharmaceuticals, Inc, Clovis Oncology, Dynavax Technologies, EPIX Pharmaceuticals, Wellstat Management Company |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Fortress Biotech employee's phone or email?
The Fortress Biotech annual revenue was $36 million in 2024.
Lindsay Rosenwald is the Chairman, Chief Executive Officer of Fortress Biotech.
40 people are employed at Fortress Biotech.
Fortress Biotech is based in Bay Harbor Islands, Florida.
The NAICS codes for Fortress Biotech are [32, 3254, 32541, 325].
The SIC codes for Fortress Biotech are [283, 28].